10-Q: DiaMedica Therapeutics Reports Second Quarter 2024 Financial Results and Provides Clinical Program Update

DiaMedica Therapeutics reported its Q2 2024 financial results, highlighting progress in its ReMEDy2 trial for acute ischemic stroke and expansion into preeclampsia treatment.

Summary

• DiaMedica Therapeutics reported a net loss of $5.1 million for the three months ended June 30, 2024, and a net loss of $10.3 million for the six months ended June 30, 2024.
• The company's research and development expenses increased to $3.9 million for the three months and $7.6 million for the six months ended June 30, 2024, driven by the ReMEDy2 clinical trial and increased staffing costs.
• General and administrative expenses decreased to $1.7 million for the three months and $3.8 million for the six months ended June 30, 2024, due to lower insurance premiums and legal fees.
• The company's cash, cash equivalents, and marketable securities totaled $54.1 million as of June 30, 2024, with working capital of $51.9 million.
• DiaMedica plans to expand its DM199 clinical development program into preeclampsia with a Phase 2 trial anticipated to cost approximately $1.5 million.
• The company expects its current cash resources to be sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company has a strong cash position and is expanding its clinical programs, it is still incurring significant losses and facing challenges with its ReMEDy2 trial. The need for future capital raises and the ongoing litigation also contribute to the neutral sentiment.

Positives

• The company's cash position is strong with $54.1 million in cash, cash equivalents, and marketable securities.
• The company successfully raised $11.7 million through a private placement.
• DiaMedica is expanding its clinical program into preeclampsia, which represents a new market opportunity.
• The company expects current cash resources to be sufficient to fund operations for at least the next 12 months.
• The company has made progress in its ReMEDy2 trial for acute ischemic stroke.

Negatives

• The company continues to incur significant operating losses, with a net loss of $10.3 million for the first six months of 2024.
• The ReMEDy2 trial has experienced slower than expected site activations and enrollment.
• The company is still in the clinical stage and does not generate revenue from product sales.
• The company is dependent on raising additional capital to fund its operations.

Risks

• The company's clinical trials may be delayed due to hospital staffing shortages, competition for research staff, and other factors.
• There are risks associated with the expansion into preeclampsia, including regulatory approvals, costs, and enrollment.
• The company may not be able to obtain additional funding on favorable terms or at all.
• The company's clinical data may not be positive, which could impact its ability to raise capital.
• The company is subject to ongoing litigation with ICON/PRA Netherlands.

Future Outlook

DiaMedica expects to continue its ReMEDy2 trial and initiate a Phase 2 trial for preeclampsia, with current cash resources sufficient to fund operations for at least the next 12 months. The company anticipates topline results from the preeclampsia trial in the first half of 2025.

Management Comments

• Management believes the ReMEDy2 trial has the potential to serve as a pivotal registration study of DM199.
• Management is working to mitigate the impact of slower than expected site activations and enrollment in the ReMEDy2 trial by expanding the trial globally.
• Management believes DM199 has the potential to lower blood pressure, enhance endothelial health, and improve perfusion to maternal organs and the placenta in preeclampsia.

Industry Context

The expansion into preeclampsia addresses a significant unmet medical need, as there are currently no approved therapeutics for preeclampsia in the United States or Europe. The company's focus on acute ischemic stroke also aligns with the need for new treatment options for patients who are not eligible for existing therapies.

Comparison to Industry Standards

• DiaMedica's approach to treating acute ischemic stroke with DM199 targets a patient population not addressed by current thrombolytic agents like tPA or Tenecteplase, or mechanical thrombectomy, which is a significant differentiator.
• The company's expansion into preeclampsia is notable, as there are no approved therapeutics for this condition in the US or Europe, presenting a significant market opportunity.
• The company's financial position, with $54.1 million in cash and marketable securities, is relatively strong compared to other clinical-stage biopharmaceutical companies, but the ongoing losses and need for future capital raises are typical for companies at this stage.
• The company's reliance on third-party collaborators for clinical trials is common in the industry, but it introduces risks related to control and timelines.

Legal Proceedings

• The company is involved in ongoing litigation with ICON/PRA Netherlands regarding clinical study data.
• The company has appealed a decision related to damages in the ICON/PRA Netherlands case, with a hearing scheduled for March 2025.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and the progress of its clinical trials.
• Employees are impacted by the company's financial stability and the success of its clinical programs.
• Patients with acute ischemic stroke and preeclampsia are potential beneficiaries of the company's drug candidates.
• The company's suppliers and vendors are impacted by its financial health and operational activities.

Next Steps

• Continue the ReMEDy2 clinical trial for acute ischemic stroke.
• Initiate the Phase 2 clinical trial for preeclampsia.
• Prepare regulatory submissions and engage study sites in Canada, Australia, and Europe for the ReMEDy2 trial.
• Monitor the results of the ReMEDy2 trial and implement additional actions as needed.
• Monitor the results of the Phase 2 preeclampsia trial.
• Continue to seek additional funding for operations.

Key Dates

Keywords

DM199, acute ischemic stroke, preeclampsia, clinical trial, ReMEDy2, biopharmaceutical, research and development, private placement, regulatory approval, financial results